News : AstraZeneca

Advanced Clinical Concepts Names Tina Vitelli as Strategic Partnerships Director

3/20/2013 1:19 PM EST - Paul Werth Associates

BRIDGEWATER, N.J., March 20, 2013 — Medical communications company Advanced Clinical Concepts (ACC) continues its growth trend with the addition of Tina M. Vitelli as strategic partnerships director. In her new role, Tina is responsible for business development, assisting with client relationships, and contributing to the company’s marketing and public relations efforts.

“Tina’s...

Nobel Media and AstraZeneca bring Nobel Laureate Elizabeth Blackburn to Korea

10/27/2012 7:00 PM EST - NOBEL MEDIA

First AstraZeneca Nobel Medicine Initiative event in Korea aims to inspire local students and scientists
Nobel Media AB, the company responsible for managing and developing media rights in connection with the Nobel Prize and AstraZeneca, a global innovation-driven biopharmaceutical company, will bring Professor Elizabeth Helen Blackburn, the 2009 Nobel Laureate in Physiology or Medicine, to Catholic University...

Nobel Media and AstraZeneca Present Nobel Laureate on China Lecture Tour

10/15/2012 4:00 AM EST - NOBEL MEDIA

University lectures aim to inspire next generation of Chinese scientists
Nobel Media AB, the company responsible for managing and developing media rights in connection with the Nobel Prize in partnership with AstraZeneca, an innovation-driven global biopharmaceutical company, are delighted to present Nobel Laureate Professor Oliver Smithies in a series of lecture events in Shanghai and Nanjing, as a part of the...

Återköp av aktier - information om utskick

6/1/2012 8:54 AM EST - AstraZeneca

Vi ser över hur vi kan effektivisera och förenkla vår kommunikation. Denna information finns framöver på bifogad länk. Informationen finns även tillgänglig på astrazeneca.se/aktieägare/aktieinformation. Detta utskick upphör därför per 1/6 2012. Vi frågor, kontakta: Ann-Leena Mikiver, presschef, 08-553 26020. http://www.londonstockexchange.com/exchange/news/market-news/market-news-home.html

REPURCHASE OF SHARES IN ASTRAZENECA PLC

5/31/2012 6:54 AM EST - AstraZeneca

AstraZeneca PLC announced that on 30 May 2012, it purchased for cancellation 700,000 ordinary shares of AstraZeneca PLC at a price of 2603 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,263,508,760. A C N Kemp Company Secretary 31 May 2012

REPURCHASE OF SHARES IN ASTRAZENECA PLC

5/30/2012 7:53 AM EST - AstraZeneca

AstraZeneca PLC announced that on 29 May 2012, it purchased for cancellation 150,000 ordinary shares of AstraZeneca PLC at a price of 2626 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,264,197,399. A C N Kemp Company Secretary 30 May 2012

REPURCHASE OF SHARES IN ASTRAZENECA PLC

5/25/2012 7:54 AM EST - AstraZeneca

AstraZeneca PLC announced that on 24 May 2012, it purchased for cancellation 153,000 ordinary shares of AstraZeneca PLC at a price of 2605 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,264,461,837. A C N Kemp Company Secretary 25 May 2012

REPURCHASE OF SHARES IN ASTRAZENECA PLC

5/24/2012 9:58 AM EST - AstraZeneca

AstraZeneca PLC announced that on 23 May 2012, it purchased for cancellation 600,000 ordinary shares of AstraZeneca PLC at a price of 2610 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,264,610,194. A C N Kemp Company Secretary 24 May 2012

Återköp av aktier i AstraZeneca PLC 17-21 maj 2012

5/22/2012 3:22 AM EST - AstraZeneca

REPURCHASE OF SHARES IN ASTRAZENECA PLC

AstraZeneca PLC announced that on 18 May 2012, it purchased for cancellation 600,000 ordinary shares of AstraZeneca PLC at a price of 2624 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,265,183,783.

A C N Kemp

Company Secretary

21 May 2012

REPURCHASE OF SHARES IN ASTRAZENECA PLC

AstraZeneca PLC announced that on 17 May...

REPURCHASE OF SHARES IN ASTRAZENECA PLC

5/16/2012 10:21 AM EST - AstraZeneca

AstraZeneca PLC announced that on 15 May 2012, it purchased for cancellation 550,000 ordinary shares of AstraZeneca PLC at a price of 2654 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,266,580,309. A C N Kemp Company Secretary 16 May 2012

Found press releases